Shire Settles Patent Dispute - Analyst Blog

By
A A A

Shire LLC, a subsidiary of Shire plc ( SHPG ) recently announced that it has entered into a settlement agreement with Anchen Pharmaceuticals, Inc., Anchen, Inc. and TWi Pharmaceuticals, Inc. Shire has resolved all pending litigation related to TWi's abbreviated new drug application (ANDA) for a generic version of Shire's Intuniv (guanfacine hydrochloride) for the treatment of attention deficit hyperactivity disorder. Anchen is TWi's filing agent in the US and authorized distributor.

Under the terms of the settlement agreement, Anchen can launch TWi's generic versions of Intuniv in the US on July 1, 2016 or earlier under certain circumstances. Shire will receive royalties on the sales of TWi's generic versions of Intuniv.

However, under certain conditions, Shire can permit Anchen to market an authorized generic version of Intuniv. Shire will receive significant royalties on the sale of the authorized generic version of Intuniv.

However, Shire's Intuniv worries do not end here. The company is fighting patent infringement lawsuits with several other companies including Teva Pharmaceuticals ( TEVA ) and Actavis Inc., who have filed ANDAs for their generic versions of Intuniv.

A trial is expected to commence on September 17, 2012. Impax Laboratories, Inc. ( IPXL ), Mylan Pharmaceuticals, Inc. ( MYL ), Watson Pharmaceuticals, Inc. ( WPI ) and Sandoz, the generic pharmaceuticals division of Novartis ( NVS ), have also filed ANDAs seeking to market their generic versions of Intuniv.

Our Recommendation

We currently have a Neutral recommendation on Shire. The stock carries a Zacks #3 Rank (Neutral rating) in the short run.

The threat of generic competition, which several of Shire's products are already facing or are likely to face, puts immense pressure on the company's pipeline.

Shire is seeking to boost its pipeline through acquisitions and collaborations. Even though encouraged by Shire's efforts to develop its pipeline, we prefer to remain on the sidelines until we gain more visibility on its progress with the pipeline.



 
IMPAX LABORATRS (IPXL): Free Stock Analysis Report
 
MYLAN INC (MYL): Free Stock Analysis Report
 
NOVARTIS AG-ADR (NVS): Free Stock Analysis Report
 
SHIRE PLC-ADR (SHPG): Free Stock Analysis Report
 
TEVA PHARM ADR (TEVA): Free Stock Analysis Report
 
WATSON PHARMA (WPI): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: ANDA , IPXL , MYL , NVS , SHPG

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

89,070,740
  • $17.26 ▲ 3.23%
78,931,485
  • $7.02 ▲ 4.46%
77,553,134
  • $6.70 ▲ 6.69%
77,023,446
  • $24.66 ▲ 0.69%
74,713,235
  • $101.80 ▲ 1.82%
72,324,726
  • $7.64 ▲ 0.79%
57,112,188
  • $17.84 ▲ 55.27%
53,320,897
  • $18.01 ▼ 4.46%
As of 12/17/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com